APR 9·TradingView▲
SNGX: Late-stage pipeline addresses rare diseases and public health, backed by strong clinical data
Soligenix, Inc. (SNGX) boasts a robust late-stage pipeline, featuring assets like HyBryte for CTCL, which target rare diseases and critical public health threats. The company's efforts are supported by strong clinical data, significant market potential, government funding, and experienced leadership. This positions SNGX for ongoing development and commercialization in these key therapeutic areas.
APR 2·TipRanks▲
Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy
Soligenix (NASDAQ: SNGX) announced positive results from a comparability study published in Oncology and Therapy, evaluating HyBryte versus Valchlor for cutaneous T-cell lymphoma (CTCL). The study showed that 60% of HyBryte-treated patients achieved treatment success after 12 weeks, compared to 20% for Valchlor, with HyBryte demonstrating greater improvement and no treatment-related adverse events. These findings suggest HyBryte is a well-tolerated and effective potential therapy for early-stage CTCL.
